Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GL-S01 is a preclinical recombinant fusion protein developed by GILongevity, a subsidiary of GI Innovation, for the prevention and treatment of sarcopenia (age-related muscle loss). The candidate is engineered using the proprietary GI-SMART platform, which enables the design of multi-targeting fusion proteins with optimized half-lives and therapeutic efficacy. While the specific molecular targets of GL-S01 remain undisclosed, the therapy is intended to address the biological mechanisms of muscle wasting to improve physical function and quality of life in aging populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GL-S01.